Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.

The entities involved

• Novo Nordisk →

  Danish pharmaceutical company

  • BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Mon 10:09
  • CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.Mon 00:08
• Merck →

  public company in Indonesia

  • Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Sat 17:22
  • Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.Fri 18:13
• Eli Lilly and Company →

  American pharmaceutical company

  • ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
  • The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59

Related events

• Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.Sep 3
• Novo Nordisk signed a licensing agreement with Orbis to explore the oral obesity market, leveraging AI platforms for drug discovery.Sun 22:22
• Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.Sep 14
• Novo Nordisk operates in Europe, North America, the Middle East, and mainland China, while MarketBeat covers both Novo Nordisk and Eli Lilly.Sep 21
• Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Jun 7